Do Hers and Hims prescribe Ozempic or Wegovy
Proactive compliance reviews of promotional materials may help reduce regulatory risk as FDA continues to monitor this evolving market. Rebecca Zadaka, Associate Attorney, Gardner Law How Gardner Law Can Help FDAs recent warning letters underscore the regulatory risk associated with compounded GLP-1 marketing, particularly where promotional claims overstate product status, safety, effectiveness, or comparability to approved drugs
What GLP-1 Patent Estates Can Learn from the Sofosbuvir Litigation History The GLP-1 class semaglutide (Novo Nordisk), tirzepatide (Eli Lilly), retatrutide (Eli Lilly, Phase III), orforglipron (Eli Lilly) is generating patent portfolios that structurally resemble the sofosbuvir estate, with base compound patents surrounded by secondary filings on formulations, dosing devices, combination regimens, and cardiovascular or renal outcome indications supported by post-approval trial data
From a chemical point of view Retatrutide is a single peptide showing activity towards three different membrane receptors
The problem is that some people experience that nausea persistently while on GLP-1s
GLP1R is expressed on beta cells in the pancreas
